Atea Pharmaceuticals, INC

Atea Pharmaceuticals announced positive Phase 3 results for its BEM/RZR regimen in treating Hepatitis C, alongside progress in its Hepatitis E drug development.

Atea Pharmaceuticals reported Q1 2026 financial results, highlighting progress in its Hepatitis C and Hepatitis E drug development programs with key Phase 3 readouts anticipated in 2026.

Atea Pharmaceuticals reported full-year 2025 financial results, provided updates on its global Phase 3 Hepatitis C Virus program, and announced the expansion of its antiviral pipeline with a new Hepatitis E Virus program.

Atea Pharmaceuticals announced its 2026 strategic priorities, including progress on its Phase 3 HCV program and initiation of a Phase 1 HEV study, alongside a strong cash position of $301.8 million.

Atea Pharmaceuticals announced its third quarter 2025 financial results, highlighted by on-track patient enrollment in its global Phase 3 Hepatitis C Virus program and the expansion into a new Hepatitis E Virus development program.

Atea Pharmaceuticals reported Q2 2025 financial results and provided a business update, highlighting significant progress in its global Phase 3 program for HCV treatment and a share repurchase initiative.

Atea Pharmaceuticals reported its Q2 2026 financial results, highlighting progress in its HCV and HEV programs, with topline results from the C-FORWARD Phase 3 trial anticipated in early Q1 2027.

Atea Pharmaceuticals, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Hepatitis C (HCV) and Hepatitis E (HEV) development programs, with cash reserves expected to fund operations through 2027.

Atea Pharmaceuticals reports reduced net loss in Q3 2025, driven by a strategic pivot to its Hepatitis C virus (HCV) program and cost-cutting measures, while maintaining a strong cash position.

Atea Pharmaceuticals reports reduced Q2 2025 net loss and operating expenses, driven by a workforce reduction and discontinuation of its COVID-19 program, while advancing its lead HCV Phase 3 clinical trials.

Atea Pharmaceuticals announces Q1 2025 results, highlighting the start of patient enrollment for the Phase 3 HCV program and a strategic review to enhance stockholder value.

Atea Pharmaceuticals reports a net loss of $31.15 million for the third quarter of 2024, while advancing its hepatitis C virus (HCV) program.

Atea Pharmaceuticals, Inc. reported a reduced net loss for 2025, driven by decreased operating expenses and the advancement of its lead Hepatitis C and Hepatitis E virus drug candidates into late-stage clinical development.

Atea Pharmaceuticals reports positive Phase 2 results for its HCV treatment and outlines plans for Phase 3 trials, while also detailing its financial performance for 2024.

Atea Pharmaceuticals has granted performance-based restricted stock units to a participant, subject to the terms of the company's 2020 Incentive Award Plan.

Atea Pharmaceuticals director Polly A. Murphy filed an amendment to correct the transaction date of a recent open-market share purchase.

Polly Murphy, a Director at Atea Pharmaceuticals, Inc., reported the acquisition of 6,100 shares of common stock.

Atea Pharmaceuticals' Chief Financial Officer, Andrea Corcoran, exercised stock options to acquire 60,000 shares of common stock at $1.24 per share.

Atea Pharmaceuticals' Chief Medical Officer, Maria Arantxa Horga, increased her direct ownership of common stock and acquired new stock options following RSU vesting.

Atea Pharmaceuticals' Chief Commercial Officer, John Vavricka, reported significant equity transactions including RSU vesting, stock option grants, and common stock sales for tax purposes.

Atea Pharmaceuticals' Chief Development Officer, Janet Hammond, increased her direct beneficial ownership of common stock and acquired new stock options following RSU vesting and tax-related dispositions.

Atea Pharmaceuticals announces its 2026 Annual Meeting of Stockholders, focusing on director elections, executive compensation, and clinical pipeline progress.

Atea Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 20, 2025, featuring proposals for director elections, auditor ratification, and executive compensation approval.

Atea Pharmaceuticals responds to shareholder nominations for board positions, emphasizing its commitment to its Phase 3 HCV program and ongoing dialogue with investors.

Driver Opportunity Partners III withdraws its nomination for J. Abbott R. Cooper to Atea Pharmaceuticals' Board of Directors at the upcoming 2025 Annual Meeting of Stockholders.

Atea Pharmaceuticals is undertaking a strategic review, cost-cutting measures, and board enhancements to improve shareholder value.

Atea Pharmaceuticals acknowledges receipt of director nominations from shareholders Bradley L. Radoff and Driver Opportunity Partners III LP for the upcoming 2025 Annual Meeting.

Atea Pharmaceuticals, Inc. has reached an agreement with the Radoff/JEC Group, leading to a new board appointment and the initiation of a $25 million share repurchase program, while the activist group terminates its formal alliance.

A group of activist investors, led by Bradley L. Radoff and Michael Torok, has nominated three individuals for election to Atea Pharmaceuticals, Inc.'s board of directors at the upcoming 2025 annual meeting, signaling a potential proxy contest.

A group of activist investors, including Bradley L. Radoff and Michael Torok, has disclosed a 5.1% beneficial ownership stake in Atea Pharmaceuticals, Inc., expressing dissatisfaction with the current board's ability to oversee a strategic review and announcing plans to nominate a competing slate of director candidates.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Atea Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Atea Pharmaceuticals Inc. following an internal realignment and disaggregated reporting.

BML Investment Partners, L.P. and Leonard Braden Michael have reported beneficial ownership of 9.9% of Atea Pharmaceuticals, Inc.'s common stock.

FMR LLC and Abigail P. Johnson have filed an Amendment No. 8 to Schedule 13G, disclosing a beneficial ownership of 11.6% in ATEA Pharmaceuticals Inc. common stock as of November 28, 2025.

FMR LLC and Abigail P. Johnson have reported a 6.7% beneficial ownership stake in ATEA Pharmaceuticals Inc. common stock as of June 30, 2025.

JPM Partners LLC and Jean-Pierre Sommadossi have disclosed significant beneficial ownership stakes in Atea Pharmaceuticals, Inc., with Dr. Sommadossi holding 10.1% of the common stock.